Regenxbio is classified as operating in the Legal Services industry, NAICS Code 5411.
Regenxbio is a publicly traded company on using the ticker symbol RGNX.
Detailed information on company financials and operating reports can be found here:
: RGNX
Note: Regenxbio's revenues are gauged from an analysis of company filings.
Investor Activity
Regenxbio has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
Date
Investors
Percent Raised
Target Size
May 28, 2015
36
100%
$71 MM
Complete list of funding rounds and total amounts in the Company Report
Trademark Applications
Trademark applications show the products and services that Regenxbio is developing and marketing.
Regenxbio doesn't have any recent trademark applications, indicating Regenxbio is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
CAMPSIITE Providing medical and scientific research information in the field of clinical trials; Medical and scientific research, namely, conducting clinical trials for others
07/29/2022
NAVXPRESS Custom manufacture of reagents for scientific and medical research and development; Custom manufacturing services, namely, production for others of clinical and medical reagents for use in gene therapy, for development of pharmaceutical preparations for use in gene therapy, and of therapeutic compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy, including gene therapy delivery of antibody biologics, enzymes and RNA interference (RNAi)
05/31/2022
NAVXCELL Biotechnological platform technology, namely, cell lines for preparation of biological vectors, and recombinant viruses for gene delivery, that includes recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific production of biologics with therapeutic effect in gene therapy, including gene therapy delivery of antibody biologics, enzymes and RNA interference (RNAi)
05/31/2022
See all trademarks and details in the Full Report.
Market Share of Regenxbio's Largest Competitors
A competitive analysis shows these companies are in the same general field as Regenxbio, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Regenxbio.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Regenxbio and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.